ArticleCureus2026
Complete Metabolic Remission in Metastatic BCOR-Altered Undifferentiated Round Cell Sarcoma Following Sequential Multimodal Therapy With Vincristine-Doxorubicin-Cyclophosphamide (VDC) Chemotherapy and Pazopanib Maintenance: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BCOR-altered undifferentiated round cell sarcomas (URCS) represent a rare entity with limited epidemiological data and variable reported outcomes, contributing to the absence of standardised therapeutic strategies. We report a 27-year-old woman with metastatic BCOR-altered URCS of the scapular region who achieved a durable complete metabolic remission following a sequential multimodal treatment strategy. The patient initially received one cycle of adriamycin-ifosfamide-mesna (AIM), which was discontinued due to toxicity, followed by five cycles of vincristine-doxorubicin-cyclophosphamide (VDC), resulting in a near-complete metabolic response. This was followed by consolidation with intensity-modulated radiotherapy (52 Gy in 26 fractions). Maintenance therapy with a reduced dose of oral pazopanib 400 mg daily, based on prior reports and tolerability considerations, was administered for 12 months. Serial fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging confirmed a sustained complete metabolic remission beyond 18 months with minimal toxicity. This case highlights the marked chemosensitivity of BCOR-altered URCS to anthracycline-vinca-based chemotherapy and suggests a potential role for vascular endothelial growth factor (VEGF)-directed maintenance therapy in sustaining remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.